HSDT - Helius Medical Technologies, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
0.1511
-0.0039 (-2.52%)
At close: 03:59PM EDT
0.1450 -0.01 (-4.04%)
After hours: 07:59PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close0.1550
Open0.1520
Bid0.0000 x 900
Ask0.0000 x 1100
Day's Range0.1500 - 0.1599
52 Week Range0.1380 - 2.7600
Volume164,824
Avg. Volume324,139
Market Cap4.263M
Beta (5Y Monthly)1.21
PE Ratio (TTM)7.55
EPS (TTM)0.0200
Earnings DateAug 14, 2023 - Aug 18, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.57
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for HSDT

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Newsfile

    Helius Medical Technologies to Present at LD Micro Invitational XIII 2023

    Newtown, Pennsylvania--(Newsfile Corp. - May 25, 2023) - Helius Medical Technologies, Inc. (NASDAQ: HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that Dane Andreeff, President and Chief Executive Officer, and Jeff Mathiesen, Chief Financial Officer, will present at LD Micro Invitational XIII 2023, at the Luxe Sunset Boulevard Hotel, California, as follows:Date: Wednesday, Ju

  • GlobeNewswire

    Helius to Highlight Innovative PoNS Therapy™ at the 2023 Consortium of Multiple Sclerosis Centers Annual Meeting, in Commemoration of World MS Day

    NEWTOWN, Pa., May 24, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies (Nasdaq:HSDT), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for gait deficits, is excited to announce its participation in the prestigious Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting. The event, which coincides with the May 30 observance of World MS Day, will take place from May 31 to June 3 at the Gaylord Rockies Resort & Convention Center in Aurora, Colo. Heli

  • GlobeNewswire

    Helius Medical Technologies, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    NEWTOWN, Pa., May 19, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that, effective May 18, 2023, its independent directors approved an equity award under Helius’ 2021 Inducement Plan, as a material inducement to an individual entering into employment with the Company. The equity award was approved in accordance with Nasdaq Listing Rule 5635(c)(4), which also requires a

  • Insider Monkey

    Helius Medical Technologies, Inc. (NASDAQ:HSDT) Q1 2023 Earnings Call Transcript

    Helius Medical Technologies, Inc. (NASDAQ:HSDT) Q1 2023 Earnings Call Transcript May 11, 2023 Helius Medical Technologies, Inc. beats earnings expectations. Reported EPS is $-0.09, expectations were $-0.11. Operator: Good day, and thank you for standing by. Welcome to the Helius Medical Technologies, Inc. Quarter One 2023 Earnings Conference Call. At this time, all participants are […]

  • Thomson Reuters StreetEvents

    Q1 2023 Helius Medical Technologies Inc Earnings Call

    Q1 2023 Helius Medical Technologies Inc Earnings Call

  • GlobeNewswire

    Helius Medical Technologies, Inc. Reports First Quarter 2023 Financial Results

    -- Company to host call at 4:30pm today -- NEWTOWN, Pa., May 11, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced results for the quarter ended March 31, 2023. First Quarter and Recent Business Updates Q1 2023 revenue of $111 thousand, compared to $190 thousand in Q1 2022, the decrease due to revenue of $120 tho

  • GlobeNewswire

    Helius Medical Technologies, Inc. to Release First Quarter 2023 Financial Results on May 11, 2023

    NEWTOWN, Pa., May 04, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that the Company will release its first quarter 2023 financial results on Thursday, May 11, 2023, after the market closes. Dane C. Andreeff, President and Chief Executive Officer, and Jeffrey S. Mathiesen, Chief Financial Officer will host a

  • GlobeNewswire

    Helius Medical Technologies to Spotlight Expanded Authorizations for its PoNS Device at 2023 American Academy of Neurology Annual Meeting, Booth 1685

    MS, Stroke and mmTBI Cover Broader Set of Indications Across North American MarketsNEWTOWN, Pa., April 17, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies (NASDAQ: HSDT) today announced it will exhibit at the American Academy of Neurology (AAN) Annual Meeting for the first time since its Portable Neuromodulation Stimulator (PoNS) device became commercially available in both the United States and Canada. Helius’s presence at the conference comes at a time when PoNS is seeking additional indi

  • InvestorPlace

    7 Sorry Pharma Stocks to Sell in April Before It’s Too Late

    Finding the best pharma stocks to sell can be an all-or-nothing kind of business. If you score on a company making a breakthrough in a new drug or treatment, the rewards can be extreme, but investing in pharma stocks can also mean heavy expenditures on research and testing for a drug that may not perform as well as scientists hope. Even if the drug does well, the extended regulatory process can be challenging for investors hoping for positive returns.InvestorPlace - Stock Market News, Stock Advi

  • American City Business Journals

    Lab Notes: Arbutus begins human testing of potential hepatitis B cure

    A roundup of recent Philadelphia-area life sciences news, including medical device makers Strados Labs and Helius Medical enter into product deals.

  • GlobeNewswire

    Helius Medical Technologies, Inc. Announces Distribution of Series B Preferred Stock to Holders of its Class A Common Stock Intended to Facilitate a Reverse Stock Split, if Necessary

    NEWTOWN, Pa., March 23, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, announced today that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series B Preferred Stock, par value $0.001 per share, for each outstanding share of Helius Class A common stock held of record on April 3, 2023. The outstanding shares of Series B Preferred Stock will vo

  • GlobeNewswire

    Helius Medical Technologies and HealthTech Connex Announce Exclusive Distribution Agreement for the Portable Neuromodulation Stimulator (PoNS®) Device

    -- Agreement extends existing partnership ---- Collaboration makes HealthTech Connex the exclusive provider of PoNS Therapy in the Vancouver area and will greatly strengthen Helius’s presence in the region -- NEWTOWN, Pa., March 22, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, and HealthTech Connex Inc. (“HTC”), a leading health technology

  • Thomson Reuters StreetEvents

    Q4 2022 Helius Medical Technologies Inc Earnings Call

    Q4 2022 Helius Medical Technologies Inc Earnings Call

  • GlobeNewswire

    Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results

    -- Full year 2022 revenue of $0.8 million, an increase of 51% over 2021 -- -- Year-end cash balance of $14.5 million -- -- Company to host call at 4:30pm today -- NEWTOWN, Pa., March 09, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced results for the quarter and full year ended December 31, 2022. Fourth Quarter

  • GlobeNewswire

    Helius Medical Technologies Announces Authorization from Health Canada to Market Portable Neuromodulation Stimulator (PoNS®) Device for the Treatment of Gait Deficit Due to Mild and Moderate Symptoms from Stroke

    -- PoNS already approved in Canada for treatment of chronic balance deficit due to mild-to-moderate traumatic brain injury (TBI) and gait deficit due to mild and moderate symptoms from Multiple Sclerosis (MS) --NEWTOWN, Pa., March 09, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits announced today that Health Canada has expanded the indication

  • GlobeNewswire

    Helius Medical Technologies, Inc. to Release Fourth Quarter and Full Year 2022 Financial Results on March 9, 2023

    NEWTOWN, Pa., March 06, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that the Company will release its fourth quarter and full year 2022 financial results on Thursday, March 9, 2023, after the market closes. Dane C. Andreeff, President and Chief Executive Officer, and Jeffrey S. Mathiesen, Chief Financial O

  • GlobeNewswire

    Helius Medical Technologies to Present at the 35th Annual ROTH Conference

    NEWTOWN, Pa., March 02, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that Dane Andreeff, President and Chief Executive Officer, and Jeff Mathiesen, Chief Financial Officer, will present at the 35th Annual ROTH Conference, March 12-14, 2023, Laguna Nigel, CA, as follows: Date:Monday, March 13, 2023Time:1:30 P

  • GlobeNewswire

    Helius Medical Technologies to Showcase PoNS Therapy™ at American Physical Therapy Association’s 2023 Combined Sections Meeting

    Physical therapists in attendance can enhance their skillset with free on-site PoNS trainingNEWTOWN, Pa., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies (NASDAQ: HSDT), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, announced today that it will be showcasing its breakthrough Portable Neuromodulation Stimulator (PoNS®) technology at the American Physical Therapy Association Combined Sections Meeting (CSM). At th

  • GlobeNewswire

    Helius Medical Technologies, Inc. Announces Preliminary Results for the Fourth Quarter and Full Year 2022

    -- Q4 2022 revenue projected to range from $275,000 to $285,000 ---- Full year 2022 revenue projected to range from $780,000 to $790,000 ---- Unaudited year end cash balance of $14.5 million -- NEWTOWN, Pa., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced preliminary, unaudited results for the quarter and full year ended December 31, 2022, and provided a corporate

  • GlobeNewswire

    Helius Medical Technologies to Present at the Virtual Q1 Investor Summit Microcap Event, January 26, 2023

    NEWTOWN, Pa., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that Dane Andreeff, President and Chief Executive Officer, and Jeff Mathiesen, Chief Financial Officer, will present at the Virtual Q1 Investor Summit Microcap Event, as follows: Date:Time:Webcast: Thursday, January 26, 20239:30 AM ETClick Here Investors who would like to schedule a 1-on-1 meeting with H

  • GlobeNewswire

    Helius Medical Technologies, Inc. Announces Participation of Neurology Center of New England in its Therapeutic Experience Program

    -- Fifth Center of Excellence added in multi-center, company-sponsored, open label observational interventional trial to evaluate the impact of subjects’ adherence to PoNS® therapy for gait improvement in Multiple Sclerosis -- NEWTOWN, Pa., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced the addition of Neurology Center of New England, P.C. (“NCNE”) to its Therapeu

  • GlobeNewswire

    Helius Extends its Patient Therapy Access Program (PTAP), Bringing the Benefits of its PoNS® Device to More People with Multiple Sclerosis

    PTAP Lowers the Cost of PoNS Therapy™ for Qualified AmericansNEWTOWN, Pa., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies (NASDAQ: HSDT) today announced the extension of a program that puts the company’s Portable Neuromodulation Stimulator (PoNS®) into the hands of qualified Americans with multiple sclerosis (MS) at a significantly reduced cost. This initiative, the Patient Therapy Access Program (PTAP), launched in June 2022 and was slated to expire at the end of last year. PTAP

  • GlobeNewswire

    Helius Launches UpScript Telehealth e-Commerce Site, Making it Easier for Americans with Multiple Sclerosis to Access Neurotech that can Improve their Ability to Walk

    New Partnership with UpScript Provides Access to Care, Delivers PoNS Devices to DoorstepsNEWTOWN, Pa., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies (NASDAQ: HSDT) launched a new e-commerce site that makes it easier for Americans experiencing issues with their gait to obtain the company’s innovative Portable Neuromodulation Stimulator (PoNS®). When combined with an exercise regimen supervised by a physical therapist, the PoNS device improves gait impairment in people with MS. Thi

  • Zacks

    Helius Medical Technologies, Inc. (HSDT) Moves to Buy: Rationale Behind the Upgrade

    Helius Medical Technologies, Inc. (HSDT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

  • GlobeNewswire

    Helius Medical Technologies, Inc. Reports Third Quarter 2022 Financial Results

    -- Total Q3 revenue up 80% over prior year ---- Cash on hand expected to fund operations through 2023 ---- Company to host call at 8:30am today -- NEWTOWN, Pa., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today reported financial results for the quarter ended September 30, 2022. Third Quarter and Recent Business Updates First full quarter of commercial availability of PoNS® in